PHASE I, DOSE-FINDING STUDY OF SUNITINIB (SU) IN COMBINATION WITH IRINOTECAN (IR) IN PATIENTS WITH ADVANCED SOLID TUMOURS

被引：0
|
作者：
Boven, E. [1 ]
Massard, C. [2 ]
Armand, J. P. [3 ]
Tillier, C. [1 ]
Hartog, V. [1 ]
Brega, N. M. [4 ]
Contouriotis, A. M. [5 ]
Law, C. N. J. [5 ]
Soria, J. [1 ]
机构：
[1] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[2] Inst Gustave Roussy, Villejuif, France
[3] Inst Claudius Regaud, Toulouse, France
[4] Pfizer Global Res & Dev, Oncology, Milan, Italy
[5] Pfizer Inc, Global Res & Dev, La Jolla, CA USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：156 / 157
页数：2
相关论文
共 50 条
  • [21] A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer
    C. Gómez-Martín
    R. Salazar
    C. Montagut
    M. Gil-Martín
    J. A. Núñez
    M. Puig
    X. Lin
    R. Khosravan
    J. M. Tursi
    M. J. Lechuga
    J. Bellmunt
    Investigational New Drugs, 2013, 31 : 390 - 398
  • [22] Phase I study of sunitinib (SU) in combination with pemetrexed (Pem) in patients (pts) with advanced solid tumors (ST)
    Nakagawa, Kazuhiko
    Okamoto, Isamu
    Shimizu, Toshio
    Miyazaki, Masaki
    Tsurutani, Junji
    Ichikawa, Yasuko
    Terashima, Masaaki
    Takeda, Masayuki
    Fumita, Soichi
    Kiriyama, Tsukasa
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S701 - S701
  • [23] A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors
    Poveda, Andres
    Oaknin, Ana
    Romero, Ignacio
    Guerrero-Zotano, Angel
    Farinas-Madrid, Lorena
    Rodriguez-Freixinos, Victor
    Mallol, Pedro
    Lopez-Reig, Raquel
    Antonio Lopez-Guerrero, Jose
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [24] A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors
    Andres Poveda
    Ana Oaknin
    Ignacio Romero
    Angel Guerrero-Zotano
    Lorena Fariñas-Madrid
    Victor Rodriguez-Freixinos
    Pedro Mallol
    Raquel Lopez-Reig
    Jose Antonio Lopez-Guerrero
    Scientific Reports, 11
  • [25] Clofarabine administered weekly to adult patients with advanced solid tumors in a phase I dose-finding study
    Cunningham, CC
    Nemunaitis, J
    Senzer, N
    Vukelja, S
    Weiss, J
    Ferrier, A
    Vukovic, V
    Weitman, S
    Richards, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 223S - 223S
  • [26] Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors
    Fornier, M. N.
    Rathkopf, D.
    Shah, M.
    Patil, S.
    O'Reilly, E.
    Tse, A. N.
    Hudis, C.
    Lefkowitz, R.
    Kelsen, D. P.
    Schwartz, G. K.
    CLINICAL CANCER RESEARCH, 2007, 13 (19) : 5841 - 5846
  • [27] A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours
    Dumez, H.
    Awada, A.
    Piccart, M.
    Assadourian, S.
    Semiond, D.
    Guetens, G.
    de Boeck, G.
    Maes, R. A. A.
    de Bruijn, E. A.
    van Oosterom, A.
    ANNALS OF ONCOLOGY, 2006, 17 (07) : 1158 - 1165
  • [28] Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
    Robert, Francisco
    Sandler, Alan
    Schiller, Joan H.
    Liu, Glenn
    Harper, Karen
    Verkh, Lev
    Huang, Xin
    Ilagan, Jennifer
    Tye, Lesley
    Chao, Richard
    Traynor, Anne M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (04) : 669 - 680
  • [29] Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
    Francisco Robert
    Alan Sandler
    Joan H. Schiller
    Glenn Liu
    Karen Harper
    Lev Verkh
    Xin Huang
    Jennifer Ilagan
    Lesley Tye
    Richard Chao
    Anne M. Traynor
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 669 - 680
  • [30] Phase I dose-finding and pharmacokinetic study of a combination of elisidepsin (E) and erlotinib (T) in patients (pts) with advanced solid tumors.
    Goel, Sanjay
    Moran, Teresa
    Coronado, Cinthya
    Ramirez, Santiago Viteri
    Chaudhary, Imran
    Ghalib, Mohammad Haroon
    Swami, Umang
    Hou, Yijuan
    Carcereny, Enric
    Alcantara, Jose
    Dios, Jorge Luis Iglesias
    De Miguel, Bernardo
    Buges, Cristina
    Rosell, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345